Health IT in the Hoosier State is taking off
The Midwest isn't usually considered a hub for health IT innovation. But a closer look at a few organizations in Indiana shows there's a plethora of healthcare-related activity brewing in Indiana.
JNJ, BioCrossroads invest in Hoosier pharma startup at work on potential hepatitis B cure
An Indiana University spinout attracted investors from Johnson & Johnson Development Corp. and BioCrossroads with novel drugs to treat, and even potentially cure, patients with hepatitis B. Assembly Pharmaceuticals received an undisclosed amount for this seed round. This funding will finance the preclinical proof of concept and help the company establish its bio labs in San Francisco, […]
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
With right CEO, this $360M collaboration could push Indiana to top of life sciences industry
Indiana has propelled itself into the upper echelons of the life sciences industry. It’s a Top Five life sciences state overall and the fourth biggest medtech state. But it still isn’t mentioned in the same breath as California or Boston. Over the next decade, that could change. A $360 million collaboration among BioCrossroads, the state’s […]
Biocrossroads picks seven Indiana health IT, life science startups to compete for venture capital
Biocrossroads, which provides money and support to Indiana’s life sciences industry, announced the seven finalists who stand to gain startup funding in its annual New Venture Competition. Six have biotech or healthcare in their sights. On Oct. 21, five of these companies will compete for $25,000 and access to the Indiana Seed II Fund‘s staff […]
Eli Lilly, Roche, device makers collaborate on new public-private research institute in Indiana
Roche and Eli Lilly are among major life science players in Indiana putting resources behind a public-private research institute that would discover and develop new health innovations. Industry leaders from the drugmakers, along with Biomet, Cook Medical, Dow AgroSciences and Indiana University Health have defined a set of common scientific interests that will be the […]
Investors have put $15.5M behind cancer drug startup to revive shelved Hsp90 inhibitor
A cancer pharmaceutical startup called Esanex generated lots of reader interest back in May when it began raising a $15 million round. The latest U.S. Security and Exchange Commission filing from Esanex (in December) shows that the round was completed with $15.5 million, and today, the Indiana Seed Investment Fund II said it participated in […]
Tackling Rising Drug Costs and Growing Popularity of GLP-1’s
See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.
Alzheimer’s disease treatment uses anti-seizure meds to slow memory loss
An Indiana neuroscience pharmaceutical company hopes it can gain entry into the market for Alzheimer’s disease treatment with experimental drugs it thinks could prevent the progression of the disease in the growing population of seniors. Based on the work of Dr. Michela Gallagher of John Hopkins University, AgeneBio of Indianapolis is working to slow the […]
Tuberculosis biotech Aarden expects polished drug by year’s end
Tuberculosis, diabetes and lupus are among the diseases targeted by Aarden Pharmaceuticals, based in Indiana. The company's technology inhibits protein tyrosine phosphatases, a step which scientists have long believed will unlock new treatments for an array of ailments.
Bioscience Vaccines grabs 400k in seed funding, begins preparation for clinical trials
Bioscience Vaccines Inc. has received a $400,000 seed investment to develop technology that enhances the effectiveness of vaccines. Bioscience Vaccines will use the funding to prepare for a Phase 1 human clinical trial. The company no doubt hopes that recent publicity surrounding vaccines for H1N1 will help it draw attention from additional investors. The funding […]